Biotech | August 23, 2021
Pfizer receives EC approval for XEIJANZ
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
_256_275.jpg)